Tower Research Capital LLC (Trc) Longeveron Inc. Transaction History

Tower Research Capital LLC (Trc)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.25 - $2.51 $3,433 - $6,894	2,747 Added 67.58%	6,812 $9,000
Q3 2023 Nov 14, 2023	SELL	$2.15 - $3.59 $3,753 - $6,268	-1,746 Reduced 30.05%	4,065 $9,000
Q2 2023 Aug 14, 2023	BUY	$2.52 - $4.0 $9,530 - $15,128	3,782 Added 186.4%	5,811 $19,000
Q1 2023 May 09, 2023	BUY	$2.66 - $4.36 $2,761 - $4,525	1,038 Added 104.74%	2,029 $5,000
Q4 2022 Feb 10, 2023	SELL	$2.81 - $39.7 $1,199 - $16,951	-427 Reduced 30.11%	991 $3,000
Q3 2022 Nov 10, 2022	BUY	$3.97 - $42.7 $3,124 - $33,604	787 Added 124.72%	1,418 $5,000
Q2 2022 Aug 15, 2022	BUY	$5.93 - $15.61 $3,741 - $9,849	631 New	631 $4,000
Q1 2022 May 12, 2022	SELL	$5.06 - $13.8 $17,816 - $48,589	-3,521 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.92 - $42.3 $10,281 - $148,938	3,521 New	3,521 $42,000
Q2 2021 Aug 16, 2021	SELL	$5.2 - $8.13 $25,355 - $39,641	-4,876 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.66 - $8.45 $27,598 - $41,202	4,876 New	4,876 $32,000

1.18K

Ticker LGVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,925,940
Market Cap $12.2M
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.